Cargando…
Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections
We have a limited arsenal with which to treat invasive fungal infections caused by Aspergillus and Mucorales. The morbidity and mortality for both pathogens remains high. A triazole antifungal, isavuconazole, was recently granted approval by the US Food and Drug Administration and the European Medic...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4898026/ https://www.ncbi.nlm.nih.gov/pubmed/27330318 http://dx.doi.org/10.2147/IDR.S81416 |